Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors

Endocrine Development

Volumn 32, Issue , 2017, Pages 165-182

  Khajavi, Noushafarin ^a   Biebermann, Heike ^a   Tschöp, Matthias ^b   DiMarchi, Richard ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL HORMONE; HORMONE RECEPTOR; PEPTIDE HORMONE; PREBIOTIC AGENT;

AGONISTS; ANIMAL; BODY WEIGHT; DRUG EFFECTS; GERMFREE ANIMAL; HUMAN; INTESTINE FLORA; METABOLISM; MOUSE; NEUROSECRETORY CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PHYSIOLOGY; RECEPTOR CROSS-TALK;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL HORMONES; GASTROINTESTINAL MICROBIOME; GERM-FREE LIFE; HUMANS; INSULIN-SECRETING CELLS; MICE; NEUROENDOCRINE CELLS; OBESITY; PEPTIDE HORMONES; PREBIOTICS; RECEPTOR CROSS-TALK; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 85027728876     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000475737     Document Type: Conference Paper

References (117)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. Rodgers RJ, Tschop MH, Wilding JP: Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5: 621-626.
3. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, et al: Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008; 105: 7257-7262.
4. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al: A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757.
5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
6. Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Kuchler D, et al: GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 2014; 63: 1422-1427.
7. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM: Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 1997; 94: 8878-8883.
8. Halaas JL, Gajiwala KS, Maffei M, Cohen SL: Weightreducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546.
9. Licinio J, Caglayan S, Ozata M, Yildiz BO, De Miranda PB, O'Kirwan F, et al: Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101: 4531-4536.
10. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103.
11. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575.
12. Scarpace PJ, Zhang Y: Leptin resistance: a prediposing factor for diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2009; 296:R493-R500.
13. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA: Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003-4009.
14. Muller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, Grant E, et al: Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 2012; 18: 383-393.
15. Lamanna C, Monami M, Marchionni N, Mannucci E: Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011; 13: 221-228.
16. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996; 334: 574-579.
17. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al: Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-274.
18. Bakris GL, Fonseca VA, Sharma K, Wright EM: Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
19. Ferrannini E, Solini A: SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
20. Zhang Q, Dou J, Lu J: Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract 2014; 105: 313-321.
21. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
22. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, et al: Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-1119.
23. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al: Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515.
24. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF: Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 479-484.
25. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al: Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
26. Monami M, Nardini C, Mannucci E: Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457-466.
27. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
28. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al: American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement -executive summary. Endocr Pract 2013; 19: 536-557.
29. Bosi E, Ellis GC, Wilson CA, Fleck PR: Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011; 13: 1088-1096.
30. Harmar AJ: Family-B G-protein-coupled receptors. Genome Biol 2001; 2:reviews3013.
31. Deacon CF: What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-124.
32. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130: 1579-1588.
33. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al: Pancreatic safety of incretinbased drugs -FDA and EMA assessment. N Engl J Med 2014; 370: 794-797.
34. Tzefos M, Olin JL: Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1294-1300.
35. Govindan J, Healey B, Kalupahana D, Singh B (eds): Exenatide Therapy in Insulin Treated Patients with Type 2 Diabetes and Obesity. Diabetologia, New York, Springer, 2008.
36. Samarasinghe Y, Shlomowitz A, Munro N, Feher M (eds): The Short Term Effects of Exenatide Therapy in Insulin Treated Patients with Type 2 Diabetes Mellitus -A New Option to Achieve Weight Loss. Diabetologia, New York, Springer, 2008.
37. Bhatia R, Viswanathan P, Chaudhuri A, Mohanty P, Bhatia V, Dandona P: Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1c in obese type 2 diabetics on insulin. Diabetes 2006; 55:A105.
38. Oyer DS, Crawford RS, Shah A, Bettenhausen S: Exenatide in diabetic patients on insulin and TZDs. Diabetes 2006; 55:A471.
39. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al: A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015; 21: 27-36.
40. Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, et al: Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 2013; 5: 209ra151.
41. Tschop MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Muller TD, et al: Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 2016; 24: 51-62.
42. Barrera JG, Sandoval DA, D'alessio DA, Seeley RJ: GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011; 7: 507-516.
43. Drucker DJ: The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
44. Orskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-711.
45. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.
46. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al: Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
47. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
48. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
49. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, et al: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 2012; 11: 107.
50. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
51. Brown JC, Dryburgh JR: A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 1971; 49: 867-872.
52. Salter JM: Metabolic effects of glucagon in the Wistar rat. Am J Clin Nutr 1960; 8: 535-539.
53. Dunning BE, Gerich JE: The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-283.
54. Woods SC, Lutz TA, Geary N, Langhans W: Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1219-1235.
55. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V: Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 1992; 262:R975-R980.
56. Geary N: Pancreatic glucagon signals postprandial satiety. Neurosci Biobehav Rev 1990; 14: 323-338.
57. Geary N, Guss J: Glucagon and the control of meal size. Appetite 1995; 24: 168.
58. Goodridge AG, Ball EG: Studies on the metabolism of adipose tissue. 18. In vitro effects of insulin, epinephrine and glucagon on lipolysis and glycolysis in pigeon adipose tissue. Comp Biochem Physiol 1965; 16: 367-381.
59. Heckemeyer CM, Barker J, Duckworth WC, Solomon SS: Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell. Endocrinology 1983; 113: 270-276.
60. Davidson I, Salter J, Best C: The effect of glucagon on the metabolic rate of rats. Am J Clin Nutr 1960; 8: 540-546.
61. Chan EK, Mackey MA, Snover DC, Schneider PD, Rucker RD Jr, Allen CE, et al: Suppression of weight gain by glucagon in obese Zucker rats. Exp Mol Pathol 1984; 40: 320-327.
62. Gelling RW, Vuguin PM, Du XQ, Cui L, Romer J, Pederson RA, et al: Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am J Physiol Endocrinol Metab 2009; 297:E695-E707.
63. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH: Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115.
64. Day JW, Gelfanov V, Smiley D, Carrington PE, Eiermann G, Chicchi G, et al: Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 2012; 98: 443-450.
65. Kim SJ, Nian C, McIntosh CH: Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and amp-activated protein kinase cascade. J Biol Chem 2007; 282: 8557-8567.
66. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR: GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 2007; 293:E1746-E1755.
67. Finan B, Muller TD, Clemmensen C, Perez-Tilve D, DiMarchi RD, Tschop MH: Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med 2016; 22: 359-376.
68. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK: Glucose-dependent insulinotropic polypeptide. Diabetes 2011; 60: 3103-3109.
69. Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, et al: Glucosedependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes 2015; 64: 72-78.
70. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI: Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-2870.
71. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM: Functional GIP receptors are present on adipocytes. Endocrinology 1998; 139: 4004-4007.
72. Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, et al: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003; 88: 4897-4903.
73. Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CH: GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 2012; 7:e40156.
74. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, et al: Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007; 117: 143-152.
75. McIntosh CH, Widenmaier S, Kim SJ: Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP). Vitam Horm 2009; 80: 409-471.
76. Kim SJ, Nian C, McIntosh CH: Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 2007; 282: 34139-34147.
77. Kim SJ, Nian C, McIntosh CH: GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res 2010; 51: 3145-3157.
78. Renner S, Fehlings C, Herbach N, Hofmann A, von Waldthausen DC, Kessler B, et al: Glucose intolerance and reduced proliferation of pancreatic betacells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010; 59: 1228-1238.
79. Day JW, Li P, Patterson JT, Chabenne J, Chabenne MD, Gelfanov VM, et al: Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J Pept Sci 2011; 17: 218-225.
80. Finan B, Yang B, Ottaway N, Stemmer K, Muller TD, Yi CX, et al: Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 2012; 18: 1847-1856.
81. Mentis N, Vardarli I, Kothe LD, Holst JJ, Deacon CF, Theodorakis M, et al: GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 2011; 60: 1270-1276.
82. Campbell JE, Drucker DJ: Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837.
83. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH: The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010; 6: 689-697.
84. Grodsky GM, Fanska RE: The in vitro perfused pancreas. Methods Enzymol 1975; 39: 364-372.
85. Taguchi N, Aizawa T, Sato Y, Ishihara F, Hashizume K: Mechanism of glucose-induced biphasic insulin release: physiological role of adenosine triphosphate-sensitive K+ channel-independent glucose action. Endocrinology 1995; 136: 3942-3948.
86. Aizawa T, Komatsu M: Rab27a: a new face in beta cell metabolism-secretion coupling. J Clin Invest 2005; 115: 227-230.
87. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
88. Doyle ME, Egan JM: Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-593.
89. Light PE, Manning Fox JE, Riedel MJ, Wheeler MB: Glucagon-like peptide-1 inhibits pancreatic ATPsensitive potassium channels via a protein kinase Aand ADP-dependent mechanism. Mol Endocrinol 2002; 16: 2135-2144.
90. Kang G, Chepurny OG, Malester B, Rindler MJ, Rehmann H, Bos JL, et al: cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. J Physiol 2006; 573: 595-609.
91. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, et al: Pancreatic glucagonlike peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999; 140: 1132-1140.
92. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, et al: Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 2010; 78: 456-465.
93. MacDonald PE, Wang X, Xia F, El-Kholy W, Targonsky ED, Tsushima RG, et al: Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 2003; 278: 52446-52453.
94. Bavec A, Hallbrink M, Langel U, Zorko M: Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regul Pept 2003; 111: 137-144.
95. Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, Langel U: Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. Biochim Biophys Acta 2001; 1546: 79-86.
96. Dyachok O, Isakov Y, Sagetorp J, Tengholm A: Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature 2006; 439: 349-352.
97. Montrose-Rafizadeh C, Wang Y, Janczewski AM, Henderson TE, Egan JM: Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. Mol Cell Endocrinol 1997; 130: 109-117.
98. 2+]i oscillations in transgenically derived beta-cells. J Biol Chem 1998; 273: 10402-10410.
99. Akiba Y, Kato S, Katsube K-i, Nakamura M, Takeuchi K, Ishii H, et al: Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochem Biophys Res Commun 2004; 321: 219-225.
100. Hisanaga E, Nagasawa M, Ueki K, Kulkarni RN, Mori M, Kojima I: Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic betacells. Diabetes 2009; 58: 174-184.
101. Casas S, Novials A, Reimann F, Gomis R, Gribble FM: Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. Diabetologia 2008; 51: 2252-2262.
102. Hiriart M, Aguilar-Bryan L: Channel regulation of glucose sensing in the pancreatic beta-cell. Am J Physiol Endocrinol Metab 2008; 295:E1298-E1306.
103. Wagner TF, Loch S, Lambert S, Straub I, Mannebach S, Mathar I, et al: Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells. Nat Cell Biol 2008; 10: 1421-1430.
104. Venkatachalam K, Montell C: TRP channels. Annu Rev Biochem 2007; 76: 387-417.
105. Togashi K, Hara Y, Tominaga T, Higashi T, Konishi Y, Mori Y, et al: TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion. EMBO J 2006; 25: 1804-1815.
106. 2+ influx and its inhibition by N-(p-amylcinnamoyl) anthranilic acid in the beta-cells: involvement of TRPM2 channels. J Cell Mol Med 2009; 13: 3260-3267.
107. 2+-release channel in beta cells. Sci Signal 2009; 2:ra23.
108. Uchida K, Dezaki K, Damdindorj B, Inada H, Shiuchi T, Mori Y, et al: Lack of TRPM2 impaired insulin secretion and glucose metabolisms in mice. Diabetes 2011; 60: 119-126.
109. Cheng H, Beck A, Launay P, Gross SA, Stokes AJ, Kinet JP, et al: TRPM4 controls insulin secretion in pancreatic beta-cells. Cell Calcium 2007; 41: 51-61.
110. 2+ signals during agonist-induced insulin secretion in pancreatic betacells. Mol Cell Endocrinol 2009; 299: 194-203.
111. 2+]i. Proc Natl Acad Sci U S A 2003; 100: 15166-15171.
112. 2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5-/-mice. Proc Natl Acad Sci U S A 2010; 107: 5208-5213.
113. Brixel LR, Monteilh-Zoller MK, Ingenbrandt CS, Fleig A, Penner R, Enklaar T, et al: TRPM5 regulates glucose-stimulated insulin secretion. Pflugers Arch 2010; 460: 69-76.
114. Uchida K, Tominaga M: The role of thermosensitive TRP (transient receptor potential) channels in insulin secretion. Endocr J 2011; 58: 1021-1028.
115. Uchida K, Tominaga M: The role of TRPM2 in pancreatic β-cells and the development of diabetes. Cell Calcium 2014; 56: 332-339.
116. Yosida M, Dezaki K, Uchida K, Kodera S, Lam NV, Ito K, et al: Involvement of cAMP/EPAC/TRPM2 activation in glucose -and incretin-induced insulin secretion. Diabetes 2014; 63: 3394-3403.
117. Shigeto M, Ramracheya R, Tarasov AI, Cha CY, Chibalina MV, Hastoy B, et al: GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. J Clin Invest 2015; 125: 4714-4728.